7 May 2025
Our ongoing Phase I study is progressing as planned, with the first results expected in early July.
3 Apr 2025
AI-powered digital twins help interpret early signals in a small Phase 2a study of a novel therapy for Alzheimer’s disease
4 Mar 2025
Leuven biotech player remynd announces its strategic transition into an organization purely focused on drug development
30 Oct 2024
Results were presented this week at the 17th annual Clinical Trials in Alzheimer’s Disease (CTAD) conference in Madrid
3 Sept 2024
remynd announces appointment of Floor Stam as CEO and Johan Cardoen as Chairman
5 Aug 2024
We published a new study in Science revealing a promising strategy to combat Alzheimer’s disease.
Remynd is located in the Arenberg Science Park, a hub of innovation and research. Our labs and offices are situated in the Bio Incubator 3 building.
